Trial Profile
Third phase III trial of ethyl eicosapentaenoic acid [LAX 101; Miraxion] in patients with Huntington's disease.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Aug 2012
Price :
$35
*
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Huntington's disease
- Focus Registrational; Therapeutic Use
- Sponsors Amarin Corporation
- 26 Nov 2007 New trial record.